Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INITIATE: SLN Identification in Early-stage Lung Cancer
NCT05555199Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of technetium Tc 99m albumin nanocolloid and indocyanine green in lung cancer, sponsored by Radboud University Medical Center. Primary endpoint: Feasibility of SLN procedure. Started Oct 2022; status: completed.
02
Drugs
technetium Tc 99m albumin nanocolloidindocyanine green
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT05555199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555199.